Amgen Panitumumab Could See Third Quarter Approval For Third-Line Colorectal Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen and development partner Abgenix are seeking priority review for the epidermal growth factor inhibitor.
You may also be interested in...
Amgen Vectibix Approved For Metastatic Colorectal Cancer
The first entirely human anti-EGFR antibody will launch in early or mid-October.
Amgen Vectibix Approved For Metastatic Colorectal Cancer
The first entirely human anti-EGFR antibody will launch in early or mid-October.
Amgen Gets Panitumumab Priority Review
Amgen's panitumumab has an estimated mid-September user fee date under FDA priority review for metastatic colorectal cancer patients failing prior chemotherapy, the company announced June 12